Category: Publications
Pharmacovigilance: a crucial issue for the health and safety of all Europeans
Pharmacovigilance in Europe: the European Commission’s proposals endanger the population
Summary
A series of public health disasters (from thalidomide in the 1960s to rofecoxib (Vioxx°) at the beginning of this century) have served to remind us of the crucial nature of pharmacovigilance. To this end, the European Commission’s proposed legislative changes represent a serious regression in the protection of European citizens.
EMA transparency draft is just window dressing
Health Action International (HAI) Europe, International Society of Drug Bulletins (ISDB) and Medicine in Europe Forum (MiEF) find that “EMEA’s draft transparency policy” fails to restore citizens’ trust in its decision-making.
Newsletter May 2009
Attachment: newslonlymay2009.pdf
Newsletter May 2009
Download NewsLetter in English (1 MB)
Download NewsLetter in Spanish (738 KB)